ZEISS Medical Technology previews refractive workflow innovations ahead of ESCRS annual meeting

News
Article

Advancements from Carl Zeiss Medical AG in the cataract and cornea space include a new intraocular lens and therapeutic laser enhancements.

A crowd of people move about a conference floor. Image credit: ©engel.ac – stock.adobe.com

ZEISS Medical Technology will present a wide array of corneal refractive and cataract innovations at the ESCRS annual meeting. Image credit: ©engel.ac – stock.adobe.com

During the upcoming European Society of Cataract & Refractive Surgeons (ESCRS) annual meeting, attendees will be able to see a full slate of ophthalmic innovations from ZEISS Medical Technology. In a press release, Carl Zeiss Medical AG spotlighted the innovations that will be on display at ESCRS 2023, which takes place 8–12 September in Vienna, Austria.

The news release1 noted several technologies that ZEISS will present at the meeting.

ZEISS demonstrates SMILE pro capabilities, teases future hyperopia applications

In an effort to expand its laser vision correction (LVC) portfolio, ZEISS announced plans for a future application for hyperopia in lenticule extraction. The company pointed at upcoming developments in its small incision lenticule extraction (SMILE®) procedures using the ZEISS VISUMAX 800. In the future, ZEISS will expand its offerings to enable hyperopia treatment with or without astigmatism using lenticule extraction. At this year’s ESCRS, the company will demonstrate “how surgeons can treat myopia using the digitally connected ZEISS VISUMAX 800 with smart robotics support.”1

Follow Ophthalmology Times Europe on LinkedIn for live coverage of ESCRS 2023

A new trifocal intraocular lens elevates cataract workflow

ZEISS will also debut a new advancement in the cataract space, a new trifocal intraocular lens (IOL) designed to maximise patient satisfaction. According to the company, the AT ELANA ® 841P combines the best of existing ZEISS technology, including "a glistening-free hydrophobic c-loop platform and a fully preloaded injector for a safe and reliable implantation."1

Dr Peter Mojžiš, PhD, FEBO, an assistant professor and third faculty at Charles University, Prague, Czech Republic, said his patients who have been implanted with the lens are very satisfied with their visual acuity. “The fully preloaded injector is very smooth, and the AT ELANA fits through a 2.2mm incision,” he stated. “The controlled unfolding of this new hydrophobic c-loop trifocal IOL and the stability in the capsular bag is excellent.”

A multimodal look at the next generation of corneal topography

The ZEISS ATLAS® 500 is a new corneal topography system which offers precise pupillometry, dry eye assessment and corneal topography.1 The device fully integrates multiple imaging modalities into one machine, which streamlines the corneal and cataract workflows. Ahead of ESCRS, Dr Edward Boshnick, owner of Global Vision Rehabilitation Centre in Florida, US, was able to try the ATLAS 500 technology. He said the images provide "amazing detail" of the anterior eye segment, and help provide a better understanding of dry eye disease.

At ESCRS, the company also will present an overview of its refreshed ZEISS VISULAS therapeutic laser portfolio and the complete corneal refractive workflow including customised solutions via ZEISS PRESBYOND. Attendees can find out more during the ESCRS meeting by visiting ZEISS Medical Technology at booth 401 in Hall B.

Reference


1. ZEISS advances cataract and corneal refractive surgical care with new workflow innovations. News release. Carl Zeiss Meditec AG. August 31, 2023. https://www.zeiss.com/meditec-ag/media-news/press-releases/2023/european-society-of-cataract-and-refractive-surgery.html
Recent Videos
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
Jennifer I. Lim, MD, FARVO, FASRS
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
© 2024 MJH Life Sciences

All rights reserved.